Cantor Fitzgerald Maintains Overweight on CymaBay Therapeutics, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on CymaBay Therapeutics (NASDAQ:CBAY) and raises the price target from $23 to $24.
November 08, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on CymaBay Therapeutics and raised the price target from $23 to $24.
The raised price target by Cantor Fitzgerald indicates a positive outlook for CymaBay Therapeutics. This could potentially lead to an increase in the stock price in the short term as it signals the analyst's confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100